Sickle Cell Screen Test · Blood

You can carry the gene for sickle cell disease your entire life without knowing it. About one in every 13 people of African descent in the United States carries sickle cell trait, and most have never been tested. If two carriers have a child together, that child has a one-in-four chance of being born with sickle cell disease, a condition that can shorten life by decades. Knowing your status before starting a family, or simply to understand your own health risks, is one of the most consequential pieces of information a single blood test can give you.

A sickle cell screen looks at the type of hemoglobin inside your red blood cells. Hemoglobin is the protein that carries oxygen from your lungs to every tissue in your body. The test identifies whether you have the normal form (hemoglobin A), or whether you carry one or two copies of an altered form called hemoglobin S (HbS). Your result falls into one of three categories: normal, carrier (trait), or disease. Each carries very different implications for your health and for any children you might have.

What This Screen Detects

Hemoglobin is built from four protein chains, two alpha and two beta. A single change in the gene that codes for the beta chain creates hemoglobin S. When oxygen levels drop, HbS molecules stick together inside red blood cells, distorting them into a rigid, sickle shape. These misshapen cells get stuck in small blood vessels, blocking blood flow and triggering episodes of severe pain, organ damage, and chronic anemia.

The screen does not measure a quantity. It identifies which types of hemoglobin are present. Modern point-of-care rapid tests like HemoTypeSC, SickleSCAN, and SICKLECHECK can detect HbS from a simple finger prick or standard blood draw in minutes, with accuracy above 97% to 100% when compared to laboratory reference methods.

Understanding Your Result

Your sickle cell screen will place you into one of three categories. Each means something different for your body and your family planning.

If your result shows trait or disease, a confirmatory test using a laboratory method such as HPLC (high-performance liquid chromatography, a technique that separates and identifies different types of hemoglobin) or hemoglobin electrophoresis (a lab method that sorts hemoglobin types by electrical charge) is recommended. These methods can distinguish between different disease gene combinations, such as HbSS, HbSC, or HbS combined with beta-thalassemia (another inherited hemoglobin disorder), which carry different severity profiles. Rapid screening tests occasionally misclassify these subtypes, particularly in cord blood samples from newborns.

Sickle Cell Trait Is Not Entirely Harmless

For decades, carrying a single copy of the sickle gene was considered medically insignificant. That view has changed. A pooled analysis of five large U.S. prospective studies following nearly 16,000 African Americans found that sickle cell trait carriers had about 60% higher odds of developing chronic kidney disease (CKD) compared to non-carriers, and nearly twice the odds of having protein in their urine, a sign of kidney damage. The risk of rapid kidney function decline was about 30% higher.

Trait carriers also face modestly elevated risks of pulmonary embolism (blood clots in the lungs) and exercise-related muscle breakdown. These risks do not affect most carriers in daily life, but they matter if you are a competitive athlete, serving in the military, or have other kidney risk factors like high blood pressure or diabetes. Knowing your trait status lets you and your doctor monitor the right things.

Sickle Cell Disease: Why Early Detection Saves Lives

For people with sickle cell disease (two copies of the abnormal gene), the stakes are dramatically higher. Without early identification and treatment, children with SCD face severe infections, strokes, acute chest syndrome (a dangerous lung complication similar to pneumonia), and organ damage beginning in the first years of life. A systematic review found that newborn screening followed by early preventive care, including preventive antibiotics and vaccinations, reduced death in children under five by roughly ten-fold compared to children diagnosed only after symptoms appeared.

A long-term cohort in East London following children identified through newborn screening showed 99% survival to age 16 for children with the most severe gene combination (HbSS), with very low rates of serious bacterial infections and stroke. A meta-analysis of adult SCD patients across North America and Europe identified key predictors of mortality: older age (about 28% higher risk per decade), elevated blood flow speed across a heart valve called the tricuspid valve (about three times higher mortality risk when elevated), and lower fetal hemoglobin, a protective form of hemoglobin that dilutes the sickling effect.

In a Kenyan birth cohort of over 15,700 infants, those born with SCD had a death rate roughly 24 times higher than infants without the condition. But among the children with SCD, those with higher levels of fetal hemoglobin had about 60% lower mortality, and those enrolled in a sickle cell clinic had about 74% lower mortality. Identification and enrollment in care is what makes the difference.

How Accurate Is the Test

Modern rapid sickle cell screening tests are remarkably accurate. A multi-country evaluation of the HemoTypeSC rapid test reported 99.5% sensitivity (meaning it correctly identifies nearly all people who carry HbS) and 99.9% specificity (meaning it almost never falsely labels someone as positive). For detecting HbSS disease specifically, the test achieved 100% accuracy. The cost in some settings is under $2 per test.

SICKLECHECK, another rapid test validated against HPLC in 400 participants, showed 99.1% sensitivity and 98.8% specificity for detecting sickle cell trait, and 97.9% sensitivity and 100% specificity for detecting sickle cell disease. SickleSCAN showed similarly high accuracy in both laboratory and field settings. A paper-based test costing about $0.07 achieved 100% sensitivity for detecting any HbS, though it was less reliable at distinguishing disease from trait.

These numbers mean that if you get a positive result on a rapid screen, it is very likely correct. But because the clinical consequences of misclassification are serious (wrong reproductive counseling, missed disease, unnecessary anxiety), confirmation with a laboratory method like HPLC or electrophoresis remains standard practice.

When Results Can Be Misleading

Unlike most blood biomarkers, the sickle cell screen is not affected by fasting, time of day, exercise, stress, or common medications. Your hemoglobin type is fixed by your genes and does not fluctuate. However, a few specific situations can produce misleading results.

• Recent blood transfusion: If you have received a red blood cell transfusion, the donor's normal hemoglobin A will be mixed with your own hemoglobin S. This can dilute the HbS signal enough to produce a false-negative result, making it look like you do not carry the gene when you do. Wait at least three months after a transfusion before screening.
• Newborns with high fetal hemoglobin: Babies in the first weeks of life have very high levels of fetal hemoglobin (HbF), which can mask HbS on some rapid tests. Cord blood samples misclassify about 3% to 4% of disease cases with some point-of-care devices. This is why newborn screening programs recommend confirmatory testing.
• Non-S hemoglobin variants: Rapid tests designed to detect HbS may miss other hemoglobin variants like HbE, HbD, or certain beta-thalassemia types. A negative sickle cell screen does not rule out all hemoglobin disorders. If your clinical picture suggests a hemoglobin disorder, a full hemoglobin analysis is warranted.
• Unreliable laboratory methods: In some settings, older solubility-based tests or poorly standardized labs can return incorrect results. In a Nigerian study, over half of parents of children with SCD reported having received an incorrect hemoglobin result from a previous test, often from a private lab.

Who Should Get This Test

In many countries, newborn screening for sickle cell disease is universal, meaning every baby is tested at birth. If you were born in a setting without universal screening, or if you are unsure whether you were ever tested, ordering this test yourself fills a gap that could have lifelong consequences.

You should know your sickle cell status if you are of African, Mediterranean, Middle Eastern, South Asian, or Caribbean descent, especially if you are considering having children. About 48% of couples in African settings report having been screened before marriage, and awareness of SCD significantly increases screening likelihood. But even in the United States, many adults have never been tested or have results from unreliable methods.

Cascade testing, where siblings and close relatives of someone with known SCD are tested, is especially high-yield. In The Gambia, cascade testing of siblings of known SCD patients found that 19% had previously undiagnosed sickle cell disease and 47% were carriers. Many of the affected siblings had symptoms but had never been tested.

Why One Test Is Usually Enough

Unlike most biomarkers in this series, the sickle cell screen does not need serial tracking. Your hemoglobin type is determined by your genes and does not change over your lifetime. A single, high-quality, confirmed result tells you everything this test can tell you. If your initial screen was done by a rapid point-of-care test and comes back positive for trait or disease, the one follow-up step is confirmatory testing by HPLC or hemoglobin electrophoresis to precisely identify your gene combination.

The exception is if your previous test was done under conditions that could have distorted the result (shortly after a transfusion, as a newborn with high fetal hemoglobin, or at a lab with questionable quality). In those cases, retesting under clean conditions is the right move.

What to Do With Your Result

If your screen is normal (HbAA), no further action is needed for sickle cell. You do not carry the gene and cannot pass it on.

If your screen shows sickle cell trait (HbAS), confirm the result with hemoglobin electrophoresis or HPLC. Then consider two things. First, if your partner also carries the trait, each pregnancy carries a 25% chance of sickle cell disease in the child. Genetic counseling before conception gives you the full picture of your options. Second, because trait carries a modestly elevated risk of chronic kidney disease, ask your doctor to check your kidney function (eGFR and urine albumin) at your next physical, and periodically thereafter, especially if you have other kidney risk factors.

If your screen shows sickle cell disease, the priority is connecting with a hematologist who specializes in hemoglobin disorders. SCD care includes disease-modifying therapy (most commonly hydroxyurea, which boosts protective fetal hemoglobin), screening for stroke risk in children, regular monitoring for kidney and lung complications, and vaccinations against infections that SCD makes more dangerous. Early, consistent, guideline-based care has transformed SCD from a childhood death sentence into a manageable chronic condition for many people.